RNAC - Cartesian Therapeutics, Inc.
IEX Last Trade
18.565
2.815 15.163%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:25:49 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$15.75
2.82
17.87%
Fundamental analysis
35%
Profitability
50%
Dept financing
25%
Liquidity
60%
Performance
16%
Performance
5 Days
-2.89%
1 Month
3.13%
3 Months
12.35%
6 Months
-23.23%
1 Year
2,485.75%
2 Year
1,626.17%
Key data
Stock price
$18.56
DAY RANGE
$15.75 - $19.03
52 WEEK RANGE
$0.75 - $41.21
52 WEEK CHANGE
-$17.91
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Carsten Brunn
Region: US
Website: www.cartesiantherapeutics.com
Employees: 64
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: www.cartesiantherapeutics.com
Employees: 64
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Cartesian Therapeutics, Inc., formerly Selecta Biosciences, Inc., is a clinical-stage company, which is engaged in ribonucleic acid (RNA) cell therapies for the treatment of autoimmune diseases.
Recent news